id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-P-0245-0007,FDA,FDA-2002-P-0245,Acknowledgment Letter From FDA DDM to Lachman Consultant Services,Other,Acknowledgement Letter/Receipt,2016-04-24T04:00:00Z,2016,4,2016-04-24T04:00:00Z,2016-04-25T03:59:59Z,2016-04-24T16:42:11Z,,0,0,090000648049a9bb
FDA-2002-P-0245-0005,FDA,FDA-2002-P-0245,"Citizen Petition From Lachman Consultant Services, Inc. SHIPPING LABEL",Other,Citizen Petition,2016-04-24T04:00:00Z,2016,4,2016-04-24T04:00:00Z,2016-04-25T03:59:59Z,2016-04-24T16:41:40Z,,0,0,090000648049a9a8
FDA-2002-P-0245-0006,FDA,FDA-2002-P-0245,"Citizen Petition From Lachman Consultant Services, Inc.",Other,Citizen Petition,2016-04-24T04:00:00Z,2016,4,2016-04-24T04:00:00Z,2016-04-25T03:59:59Z,2016-04-24T16:41:59Z,,0,0,090000648049a9b6
FDA-2002-P-0245-0003,FDA,FDA-2002-P-0245,"Final Response from FDA CDER to Lachman Consultant Services, Inc.",Other,LET-Letter,2003-11-12T05:00:00Z,2003,11,,,2016-04-24T16:26:09Z,,0,0,090000648049a9c6
FDA-2002-P-0245-0002,FDA,FDA-2002-P-0245,FDA Determination that Wydase (Hyaluronidase) Inj. was not Withdrawn for Safety or Effectiveness Reasons 68 FR 62810,Notice,N-Notice,2003-11-10T05:00:00Z,2003,11,2003-11-05T05:00:00Z,,2016-04-24T16:19:16Z,68,0,0,090000648049a9c3
FDA-2002-P-0245-0001,FDA,FDA-2002-P-0245,"Interim Response From FDA CDER to Lachman Consultant Services, Inc.",Other,LET-Letter,2003-05-20T04:00:00Z,2003,5,,,2016-04-24T16:26:58Z,,0,0,090000648049a96d